Related Experiment Video
Updated: Jul 4, 2026
11:58
Primary Culture of Mouse Dopaminergic Neurons
Published on: September 8, 2014
Dopaminergic neuron-specific oxidative stress caused by dopamine itself
Ikuko Miyazaki1, Masato Asanuma
1Department of Brain Science, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan. miyazaki@cc.okayama-u.ac.jp
Acta Medica Okayama
|July 4, 2008
Summary
Dopamine quinones cause neurotoxicity by damaging proteins and are linked to neurodegenerative diseases. This review covers dopamine quinone
Area of Science:
- Neuroscience
- Biochemistry
- Toxicology
Background:
- Oxidative stress from dopamine metabolism contributes to neurotoxicity.
- Dopamine and DOPA quinones are cytotoxic to dopaminergic neurons.
- Quinone formation links to mitochondrial dysfunction, inflammation, and protein damage.
Purpose of the Study:
- Review the pathogenicity of dopamine quinone formation.
- Discuss neuroprotective strategies against dopamine quinone-induced neurotoxicity.
Main Methods:
- Literature review of recent studies on dopamine quinone toxicity.
- Analysis of the role of quinone formation in neurodegenerative disease pathogenesis.
Main Results:
- Dopamine quinones irreversibly alter protein function via 5-cysteinyl-catechol adducts.
- Quinone formation is implicated in various cellular dysfunctions relevant to neurodegeneration.
Conclusions:
- Dopamine quinone toxicity is a key factor in dopaminergic neurodegeneration.
- Understanding quinone formation is crucial for developing neuroprotective therapies.
Related Concept Videos
01:29Drugs Affecting Neurotransmitter Synthesis
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase, which converts...
01:24Parkinson Disease ll: Pathophysiology
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
01:24Parkinson's Disease: Treatment
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
01:24Parkinson Disease l: Introduction
Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
01:15Parkinson's Disease: Overview
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
01:29Excitatory and Inhibitory Effects of Neurotransmitters
When an action potential reaches the presynaptic axon terminal, it releases neurotransmitters from the neuron into the synaptic cleft at a chemical synapse. The released neurotransmitter can be excitatory or inhibitory. The critical criteria commonly used to determine whether a molecule is a neurotransmitter at a chemical synapse are the molecule's presence in the presynaptic neuron. Second, its release is in response to strong presynaptic depolarization. And lastly, the presence of specific...